Literature DB >> 26303047

Patients with refractory reflux symptoms: What do they have and how should they be managed?

P J Kahrilas1, L Keefer1, J E Pandolfino1.   

Abstract

With the widespread use of proton pump inhibitors (PPIs), the frontier of treating reflux disease has shifted from refractory esophagitis to PPI-refractory symptoms. However, symptoms are inherently less specific than mucosal disease and, as noted by Herregods et al. in their contribution appearing in this issue of Neurogastroenterology and Motility, patients with refractory gastroesophageal reflux disease (GERD) symptoms often do not have GERD. This review discusses potential etiologies for PPI-refractory symptoms. Three major concepts are explored: subendoscopic esophagitis, weakly acidic reflux events, and alternative explanations for persistent symptoms. With respect to subendoscopic esophagitis and unsuppressed reflux, ample evidence exists that these are present in PPI-refractory patients. The problem is that these findings are also often present in substantial numbers of individuals with a satisfactory response to PPI therapy. Hence, the emphasis shifts to determinants of symptom perception. The major conclusion of the review is that psychogenic factors such as hyperalgesia, allodynia, hypervigilance, and heightened anxiety are the most plausible explanations as the dominant determinants of PPI-refractory symptoms.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  esophagus; functional disease; reflux disease

Mesh:

Substances:

Year:  2015        PMID: 26303047      PMCID: PMC4551076          DOI: 10.1111/nmo.12644

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  35 in total

1.  Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.

Authors:  M F Vela; L Camacho-Lobato; R Srinivasan; R Tutuian; P O Katz; D O Castell
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

2.  Role of E-cadherin in the pathogenesis of gastroesophageal reflux disease.

Authors:  Biljana Jovov; Jianwen Que; Nelia A Tobey; Zorka Djukic; Brigid L M Hogan; Roy C Orlando
Journal:  Am J Gastroenterol       Date:  2011-03-29       Impact factor: 10.864

3.  Mucosal impedance discriminates GERD from non-GERD conditions.

Authors:  Fehmi Ates; Elif Saritas Yuksel; Tina Higginbotham; James C Slaughter; Jerry Mabary; Robert T Kavitt; C Gaelyn Garrett; David Francis; Michael F Vaezi
Journal:  Gastroenterology       Date:  2014-10-16       Impact factor: 22.682

4.  Endoscopic Mucosal Impedance Measurements Correlate With Eosinophilia and Dilation of Intercellular Spaces in Patients With Eosinophilic Esophagitis.

Authors:  David A Katzka; Karthik Ravi; Debra M Geno; Thomas C Smyrk; Prasad G Iyer; Jeffrey A Alexander; Jerry E Mabary; Michael Camilleri; Michael F Vaezi
Journal:  Clin Gastroenterol Hepatol       Date:  2015-01-13       Impact factor: 11.382

Review 5.  Functional esophageal disorders.

Authors:  Jean Paul Galmiche; Ray E Clouse; András Bálint; Ian J Cook; Peter J Kahrilas; William G Paterson; Andre J P M Smout
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

6.  Patients with refractory reflux symptoms often do not have GERD.

Authors:  T V K Herregods; M Troelstra; P W Weijenborg; A J Bredenoord; A J P M Smout
Journal:  Neurogastroenterol Motil       Date:  2015-06-18       Impact factor: 3.598

7.  Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy.

Authors:  Frank Zerbib; Sabine Roman; Alain Ropert; Stanislas Bruley des Varannes; Philippe Pouderoux; Ulriikka Chaput; François Mion; Eric Vérin; Jean-Paul Galmiche; Daniel Sifrim
Journal:  Am J Gastroenterol       Date:  2006-07-18       Impact factor: 10.864

8.  Effects of anxiety and depression in patients with gastroesophageal reflux disease.

Authors:  Boudewijn F Kessing; Albert J Bredenoord; Caroline M G Saleh; André J P M Smout
Journal:  Clin Gastroenterol Hepatol       Date:  2014-12-09       Impact factor: 11.382

9.  A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.

Authors:  Peter J Kahrilas; John Dent; Karsten Lauritsen; Peter Malfertheiner; Hans Denison; Stefan Franzén; Goran Hasselgren
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10-22       Impact factor: 11.382

10.  Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the Esohisto project.

Authors:  Roberto Fiocca; Luca Mastracci; Robert Riddell; Kaiyo Takubo; Michael Vieth; Lisa Yerian; Prateek Sharma; Paula Fernström; Magnus Ruth
Journal:  Hum Pathol       Date:  2009-10-01       Impact factor: 3.466

View more
  17 in total

Review 1.  The Proton Pump Inhibitor Nonresponder: a Behavioral Approach to Improvement and Wellness.

Authors:  Megan E Riehl; Joan W Chen
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 2.  Overlap Between GERD and Functional Esophageal Disorders-a Pivotal Mechanism for Treatment Failure.

Authors:  Ofer Z Fass; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03

3.  Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease.

Authors:  T H Taft; J R Triggs; D A Carlson; L Guadagnoli; K N Tomasino; L Keefer; J E Pandolfino
Journal:  Aliment Pharmacol Ther       Date:  2018-03-12       Impact factor: 8.171

Review 4.  Refractory Heartburn: A Challenging Problem in Clinical Practice.

Authors:  Gerson Domingues; Joaquim Prado P Moraes-Filho; Ronnie Fass
Journal:  Dig Dis Sci       Date:  2018-01-20       Impact factor: 3.199

Review 5.  An update on current treatment strategies for laryngopharyngeal reflux symptoms.

Authors:  Amanda J Krause; Erin H Walsh; Philip A Weissbrod; Tiffany H Taft; Rena Yadlapati
Journal:  Ann N Y Acad Sci       Date:  2021-12-17       Impact factor: 6.499

6.  Psychosocial Distress and Quality of Life Impairment Are Associated With Symptom Severity in PPI Non-Responders With Normal Impedance-pH Profiles.

Authors:  Rena Yadlapati; Michael Tye; Laurie Keefer; Peter J Kahrilas; John E Pandolfino
Journal:  Am J Gastroenterol       Date:  2017-09-12       Impact factor: 10.864

7.  Low-Dose Tricyclics for Esophageal Hypersensitivity: Is it all Placebo Effect?

Authors:  Laurie Keefer; Peter J Kahrilas
Journal:  Am J Gastroenterol       Date:  2016-02       Impact factor: 10.864

8.  Esophageal hypervigilance is prevalent across gastroesophageal reflux disease presentations.

Authors:  Livia Guadagnoli; Rena Yadlapati; Tiffany Taft; John E Pandolfino; Michael Tye; Laurie Keefer
Journal:  Neurogastroenterol Motil       Date:  2021-01-11       Impact factor: 3.960

9.  Esophageal Epithelial-Derived IL-33 Is Upregulated in Patients with Heartburn.

Authors:  Hiroo Sei; Tadayuki Oshima; Jing Shan; Liping Wu; Takahisa Yamasaki; Takuya Okugawa; Takashi Kondo; Toshihiko Tomita; Hirokazu Fukui; Jiro Watari; Hiroto Miwa
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

10.  Esophageal Body Motility for Clinical Assessment in Patients with Refractory Gastroesophageal Reflux Symptoms.

Authors:  Liuqin Jiang; Bixing Ye; Ying Wang; Meifeng Wang; Lin Lin
Journal:  J Neurogastroenterol Motil       Date:  2017-01-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.